Eton Pharmaceuticals (NASDAQ:ETON) vs. Aravive (NASDAQ:ARAV) Head to Head Comparison

Aravive (NASDAQ:ARAV) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aravive and Eton Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0	0	0	0	0.00
Eton Pharmaceuticals	0	0	3	0	3.00

Eton Pharmaceuticals has a consensus price target of $27.67, indicating a potential upside of 133.87%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Aravive.

Insider and Institutional Ownership

35.8% of Aravive shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aravive and Eton Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Eton Pharmaceuticals	-15.81%	-36.29%	-16.84%

Valuation & Earnings

This table compares Aravive and Eton Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	$6.99 million	0.42	-$76.32 million	N/A	N/A
Eton Pharmaceuticals	$39.01 million	8.13	-$940,000.00	($0.15)	-78.87

Eton Pharmaceuticals has higher revenue and earnings than Aravive.

Risk and Volatility

Aravive has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

About Aravive

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.